Intelligence / Healthtech / PMA Approvals / Boston Scientific Corp
Boston Scientific Corp
9 Sept 2026: Device change approved (PMA) · WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems. Recorded in the openFDA device PMA data.
- Decided
- 9 Sept 2026
- Device
- WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems
- Specialty
- Neurology
- Type
- Supplement (Normal 180 Day Track)
- Reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Reference
- P030017 S396
- Location
- Valencia, CA
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Find the decision makers at Boston Scientific Corp
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Boston Scientific Corp in our registers.
More in Neurology
PMA Approvals
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.